|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Covestro_AG
gptkb:Monsanto
|
|
gptkbp:advertising
|
gptkb:Dr._Michael_Koenig
gptkb:Dr._Klaus_Schaefer
gptkb:Dr._Heiko_Schaefer
|
|
gptkbp:clinical_trial
|
post-marketing studies
Phase III trials
ongoing clinical trials
Phase I trials
Phase II trials
|
|
gptkbp:educational_programs
|
gptkb:Dr._Andreas_Schaefer
|
|
gptkbp:employees
|
approximately 100,000
|
|
gptkbp:founded
|
1863
|
|
gptkbp:founder
|
gptkb:Friedrich_Bayer
|
|
gptkbp:governed_by
|
gptkb:Dr._Klaus_Schaefer
gptkb:Dr._Michael_Schaefer
|
|
gptkbp:has_authority_over
|
gptkb:Dr._Peter_Schaefer
|
|
gptkbp:headcount
|
gptkb:Dr._Andreas_Schaefer
|
|
gptkbp:headquarters
|
gptkb:Leverkusen,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bayer Pharmaceuticals
|
|
gptkbp:investment
|
gptkb:Dr._Klaus_Schaefer
|
|
gptkbp:operates_in
|
global market
|
|
gptkbp:parent_company
|
gptkb:Bayer_AG
|
|
gptkbp:partnership
|
gptkb:Blue_Rock_Therapeutics
gptkb:Evotec_AG
gptkb:Loxo_Oncology
gptkb:CRISPR_Therapeutics
gptkb:Ginkgo_Bioworks
|
|
gptkbp:partnerships
|
gptkb:Dr._Andreas_Schaefer
gptkb:Dr._Peter_Schaefer
|
|
gptkbp:products
|
gptkb:Xarelto
gptkb:Eylea
gptkb:Adempas
gptkb:Stivarga
aspirin
|
|
gptkbp:regulatory_compliance
|
gptkb:Dr._Thomas_Schaefer
gptkb:Dr._Thomas_K._Schaefer
|
|
gptkbp:research
|
gptkb:Dr._Monika_Lessl
|
|
gptkbp:research_focus
|
oncology
radiology
women's health
ophthalmology
cardiovascular
|
|
gptkbp:revenue
|
approximately €41 billion (2020)
|
|
gptkbp:risk_factor
|
gptkb:Dr._Michael_Schaefer
|
|
gptkbp:subsidiary
|
gptkb:Bayer_Health_Care
gptkb:physicist
gptkb:Bayer_Animal_Health
|
|
gptkbp:supply_chain
|
gptkb:Dr._Peter_Schaefer
|
|
gptkbp:sustainability_initiatives
|
gptkb:Bayer's_Digital_Farming_Initiative
Bayer's Climate Program
Bayer's Health for All Program
Bayer's Sustainability Program
Bayer's Food for All Program
|
|
gptkbp:tactics
|
gptkb:Dr._Klaus_Schaefer
gptkb:Dr._Thomas_Schaefer
|
|
gptkbp:bfsParent
|
gptkb:physicist
|
|
gptkbp:bfsLayer
|
2
|